leadf
logo-loader
viewFrontier IP Group PLC

Frontier IP investee company Exscientia teams up with US biotech in AI drug discovery collaboration

Exscientia will deploy its AI drug discovery platform Centaur Chemist to design pre-clinical drug candidates for the joint venture

molecule
With partner Rallybio it wants to find small molecule treatments for rare diseases, of which there are 7-8,000 affecting up to 30mln people in the US and Europe

Frontier IP (LON:FIPP) said an investee company specialising in artificial intelligence has signed a drug discovery deal with an American biotech.

Exscientia, in which Frontier holds a 3.25% stake, is teaming up with Rallybio to find small molecule treatments for rare diseases, of which there are 7-8,000 affecting up to 30mln people in the US and Europe.

Exscientia will deploy its AI drug discovery platform Centaur Chemist to design pre-clinical drug candidates for the joint venture.

"There is a huge potential for artificial intelligence to revolutionise and democratise rare disease drug discovery,” said chief executive, Andrew Hopkins.

“AI can fast track, simplify and lower the price of research and we are thrilled to be partnering with Rallybio to achieve this.

“The future of drug discovery in rare diseases is to be able to address the need for precision engineered drugs at scale and our collaboration with Rallybio is the first step in this direction.”

Financial terms of the collaboration were not disclosed.

Quick facts: Frontier IP Group PLC

Price: 70 GBX

AIM:FIPP
Market: AIM
Market Cap: £38.5 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Frontier IP Group PLC named herein, including the promotion by the Company of Frontier IP Group PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Frontier IP Group teams up with University of Cambridge to tackle gum disease

Frontier IP Group PLC's (LON:FIPP) Neil Crabb discusses with Proactive London's Andrew Scott a new joint project between themselves and the University of Cambridge to tackle gum disease. The study's received a £52,891 grant from the National Biofilms Innovation Centre (NBIC). The...

on 19/6/20

2 min read